GE HealthCare Technologies Inc.

NASDAQ · GEHC
76.57+0.15+0.20%as of Oct 30, 2026

GE HealthCare Technologies Inc. (“GE HealthCare,” the “Company,” “our,” “us,” or “we”) is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world’s most complex diseases. We have approximately 54,000 colleagues dedicated to our purpose to create a world where healthcare has no limits. Serving patients and providers for nearly 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine to help clinicians deliver more personalized, precise patient care. This is complemented by our broad service capabilities and dedication to quality and integrity with a strong operational culture, supported by our lean business system, Heartbeat. We generate revenue from the sale of medical devices, consumable products, service capabilities, and AI-enabled cloud and software solutions. We serve customers in over 160 countries with a global team of approximately 9,700 sales professionals and 8,900 field service engineers. Our customers are hospitals, health systems, and researchers, including public, private, academic, and government institutio

From the 10-K filed Feb 4, 2026

CEO
Mr. Peter J. Arduini
Sector
Healthcare
Industry
Medical - Devices
Employees
54,000
Headquarters
Chicago, IL
Fiscal year end
December
1 year+1.72 (+2.30%)
GEHC+2.30%
$60$70$80$90
$76.57
40MVol
Oct '25Jan '26Mar '26Jun '26Aug '26Oct '26
FundalyzePowered by fundalyze.ai
58.6889.59

as of Oct 22, 2026 · today 76.57, 58% of the way from low to high

Yield0.19%trailing 12 months
Annual rate$0.145per share · quarterly
Last dividend$0.04ex-date Oct 23, 2026
Payout ratio3.0%of net income, trailing
5-year growth—needs six years of dividends
Years of growth22 years in a row

Valuation

Market cap$34.59Bas of Oct 22, 2026
P/E16.1×TTM · Q4 2025 – Q3 2026
P/S1.6×TTM · Q4 2025 – Q3 2026
P/B3.0×Q3 2026
Dividend yield0.19%trailing 12 months

Results, trailing twelve months

Revenue$21.64BTTM · Q4 2025 – Q3 2026
Net income$2.15BTTM · Q4 2025 – Q3 2026
Diluted EPS$4.75TTM · Q4 2025 – Q3 2026
Gross margin39.9%TTM · Q4 2025 – Q3 2026

Balance and cash

Enterprise value—Q3 2026
Long-term debt$9.97BQ3 2026
Free cash flow$1.89BTTM · Q4 2025 – Q3 2026
Stock-based comp.$152.00MTTM · Q4 2025 – Q3 2026

Shares and market

Shares outstanding451.69Mas of Nov 1, 2026
Average volume3.89Mshares a day, last 3 months
Beta0.848

Financial statements

Total revenues +4.8% $19.67B → $20.63B, year ended Dec 31, 2025

Comps

Valuation, growth and margins against the closest competitors

Filings

10-K filed Feb 4, 2026 · 10-Q Oct 28, 2026

FilingFiled
10-Q for Quarter Ended September 2026Oct 28, 2026
10-Q for Quarter Ended June 2026Jul 29, 2026
10-Q for Quarter Ended March 2026Apr 29, 2026
10-K for Fiscal Year Ended December 2025Feb 4, 2026

Insiders

No sales $6.42M bought · open market, 12 months to May 22, 2026

InsiderTypeValue
Kevin LoboMay 22, 2026Purchase$641.80K ↗
Rodney F HochmanMay 12, 2026Purchase$100.36K ↗
Watkin Phoebe L. YangMay 8, 2026Purchase$63.01K ↗
Lawrence H Culp JRMay 6, 2026Purchase$5.00M ↗

Funds (13F)

87.8% held by 1,269 managers · as of Sep 30, 2026

ManagerValueChange
Dodge & Cox$2.42B+6.55M (+20.9%)
BlackRock, Inc.$2.40B+1.48M (+4.1%)
VANGUARD CAPITAL MANAGEMENT LLC$1.90B+860.17K (+3.0%)
STATE STREET CORP$1.34B+323.09K (+1.6%)
VANGUARD PORTFOLIO MANAGEMENT LLC$1.30B+1.09M (+5.7%)

Congress

17 trades 8 sales · 9 purchases · 4 members, 12 months

MemberTypeAmount
Ro KhannaSep 11, 2026Purchase$1K–$15K
Ro KhannaAug 3, 2026Purchase$1K–$15K
Ro KhannaJun 30, 2026Purchase$1K–$15K
Ro KhannaJun 30, 2026Purchase$1K–$15K

Short interest

4.30% of float · 5.13 days to cover · Oct 15, 2026

Short position, last two years · near a 2-year high

Source: FINRA

Headlines indexed by The GDELT Project ↗, matched by company name, so one may be about something else. Each opens on its publisher’s site.

Company data reported to the SEC on EDGAR (CIK 1932393).

Everything on GEHC, in full

Every fiscal year and quarter as filed, the filing reader with highlights and AI summaries, insider and fund activity, congressional trades, short interest history, earnings calls, the full price history and every peer. A 7-day free trial, then a subscription.

Start your free trial